Complete adverse effect profile including incidence rates and management
Important Safety Information
This is not a complete list of all possible side effects. Contact your healthcare provider if you experience any unexpected symptoms. For serious or life-threatening side effects, seek emergency medical attention immediately.
6 ADVERSE REACTIONS The most common adverse reactions (incidence ≥2%) were conjunctival hemorrhage, delayed dark adaptation, foreign body sensation, eye pain, suture related complications, miosis, conjunctival hyperemia, eye pruritus, ocular discomfort, vitreous hemorrhage, blurred vision, headache, dry eye, eye irritation, cataract progression or formation, vitreous floaters, severe vision loss, eye discharge, anterior chamber cell, iridocyclitis.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Neurotech at 1- 833-963-9275 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described in this section reflects exposure to ENCELTO in two clinical trials, Study 1 (NTMT-03-A) and Study 2 (NTMT-03-B) and are pooled for analysis.
A total of 117 patients received ENCELTO, and 111 patients underwent a sham procedure and were followed for a duration of 24 months [ see Clinical Studies (14) ].
Serious adverse reactions occurred in six patients (5%) including suture related complications (n=5) and implant extrusion (n=1).
Table 1 lists the most common adverse reactions that occurred in > 2% patients and with higher frequency in ENCELTO group compared to Sham group in Study 1 and Study
Adverse Reactions occurring in ≥2% of Patients and with higher frequency in ENCELTO group compared to Sham group in ENCELTO studies* Adverse Reactions ENCELTO (N=117) n (%) Sham (N=111) n (%) Conjunctival hemorrhage 36 (31) 29 (26) Delayed dark adaptation 27 (23.1) 1 (1) Foreign body sensation in eyes 18 (15) 15 (13.5) Eye pain 18 (15) 10 (9) Suture related complication** 18 (15.4) 3 (2.7) Miosis 18 (15.4) 0 (0.0) Conjunctival hyperemia 13 (11) 9 (8) Eye pruritus 10 (9) 4 (3.6) Ocular discomfort 10 (9) 1 (1) Vitreous hemorrhage 10 (8.5) 0 (0.0) Vision blurred 8 (7) 4 (4) Headache 8 (7) 1 (1) Dry eye 7 (6) 2 (2) Eye irritation 6 (5.1) 2 (2) Cumulative cataract incidence 6 (5) 0 (0) Vitreous floaters 6 (5) 0 (0.0) Severe visual loss>15 letters*** 4 (3) 0 (0) Eye discharge 4 (3.4) 1 (0.9) Anterior chamber cell 4 (3.4) 0 (0.0) Iridocyclitis 3 (2.6) 0 (0) * Pooled data from Study 1 and Study 2;
Adverse reaction rates were comparable between the two studies **Suture related complications include exposed suture, foreign body sensation, conjunctival wound dehiscence, painful sutures, suture irritation, suture granuloma, scleral wound opening, and itchy suture *** Includes one case of visual loss due to cataract formation which remained unresolved at the end of the study
5 WARNINGS AND PRECAUTIONS ENCELTO implantation has been associated with severe vision loss, infectious endophthalmitis, retinal tears and/or detachment, vitreous hemorrhage, implant extrusion, cataract formation, suture related complications, and delayed dark adaptation.
Patients should be instructed to report signs or symptoms that could be associated with these events without delay.
Additional surgical and/or medical management may be required.
( 5.1 , 5.2 , 5.3 , 5.4 , 5.5 , 5.6 , 5.7 , 5.8 ) Vitreous Hemorrhage: Temporarily discontinue antithrombotic medication prior to ENCELTO insertion surgery to reduce the risk of implantation related vitreous hemorrhage.
Vitreous hemorrhages occurring greater than one year from implantation could be a sign of ENCELTO extrusion.
Like all medications, Encelto can cause side effects. However, not everyone who takes this medication will experience them. Many side effects are dose-dependent and may improve as your body adjusts to the medication. Others may require dose adjustment or medical attention.
Contact your healthcare provider promptly if you experience:
Seek immediate emergency medical care if you experience signs of: